4
subunits and four pore-forming inwardly-rectifying potassium (Kir6.x) subunits (Proks and Ashcroft, 2009) . They act as metabolic sensors that regulate potassium flux and couple membrane excitability to cellular energy metabolism. K ATP channels are also located on the mitochondrial inner membrane, where they participate in the control of mitochondrial volume and ATP synthesis (Cancherini et al., 2003) . It is clear that K ATP channel is a major component of the inflammatory response following brain injury. We and others have demonstrated that it regulates the reactive state of microglia, controls the release of inflammatory mediators, such as nitric oxide (NO) and tumor necrosis factor-alpha (TNFα), and modifies phagocytic activity (Zhou et al., 2008; Virgili et al., 2011; Ortega et al., 2012) . Despite these findings, the role of K ATP channel in the neurogenesis associated with inflammatory conditions is still largely unknown. Diazoxide (7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide; Dzx) is a wellknown drug that opens K ATP channels showing high affinity for mitochondrial K ATP (mito K ATP ) channels (Ashcroft and Gribble, 2000; Rodríguez et al., 2013) . Dzx activates K ATP channels in pancreatic cells and the smooth muscle of blood vessels, which results in the inhibition of insulin secretion and vasorelaxation (Richer et al., 1990; Petit and Loubatières-Mariani, 1992 ) and a subsequent increase in the plasma glucose concentration. Because of that, Dzx has been approved and used since the 1970s for treating malignant hypertension and hypoglycemia (Koch-Weser, 1976) . Oral Dzx crosses the blood brain barrier (Kishore et al., 2011) and exerts neuroprotective effects in the CNS. Previous studies have demonstrated that oral administration of Dzx ameliorates disease progression and causes neuroprotection in animal models of placed in a stereotaxic instrument (David Kopf, Carnegie Medicin, Sweden) with the incisor bar set at -3.3 mm. The stereotaxic coordinates were 3.3 mm caudal to bregma, 2.2 mm lateral to bregma, and 2.9 mm ventral from dura, according to the Atlas of Paxinos and Watson (1986) . For the unilateral intracerebral injection into the hippocampal parenchyma, we used a 5.0-µl Hamilton syringe and an infusion pump (CMA/100; Carnegie Medicin, Sweden). A volume of 0.5 µl was injected over 5 minutes. Rats received either a single microinjection of 20 nmol NMDA diluted in 50 mM phosphate buffered saline (PBS; pH 7.4) (NMDA group) or a microinjection of 50 mM PBS (pH 7.4) (sham group).
To study the effects of Dzx, this drug was administered daily per os from the 8th day until the day of sacrifice using an animal-feeding needle of size 76.2 mm from Harvard Apparatus (Holliston, MA, USA). Some rats were administered either 1 mg/kg Dzx (treated group) or diluent (0.3% DMSO in water, vehicle group). A total of 120 rats were distributed into the following groups (12 rats per group): Sham rats (sacrificed on days 5, 15 or 38 post-injection); Sham + Dzx rats (sacrificed on day 15 post-injection, treated with Dzx for 7 days, or sacrificed on day 38 post-injection, treated with Dzx for 30 days); NMDA 5 days (sacrificed on day 5 post-lesion); NMDA 15 days (sacrificed on day 15 post-lesion); NMDA 38 days (sacrificed on day 38 post-lesion) NMDA 15 days + Dzx (sacrificed at post-lesion day 15, treated with Dzx for 7 days) NMDA 38 days + Dzx (sacrificed on day 38 post-lesion, treated with Dzx for 30 days). Half of the animals (6 rats in each group) were used for biochemical studies and the other half were used for histological investigations (Figure 1 ). The Dzx and NMDA doses were chosen according to previous studies (Virgili et al., 2011; Rodríguez et al., 2013; Batlle et al., 2015) .
To determine the effects of Dzx treatment on glycaemia, we monitored blood glucose levels in NMDA+Dzx rats before and 2 hours after Dzx treatment, every two days.
Glucose measurements were performed using an Accu-ChekTM Aviva glucometer (Roche Diagnostics, Basel, Switzerland). Blood samples were obtained from the distal part of the tail. According to the animal welfare guidelines, glucose concentrations higher than 176 mg/dL were considered hyperglycemic. The selected Dzx dose did not affect glycemia in rats ( Figure 2A ). As they were used at low concentrations, the anesthetics did not interfere with the function of the NMDA receptors (Batlle et al., 2015) . 7
To determine the proliferation peak induced by the NMDA injection into the rat hippocampus, 6 sham and 6 NMDA rats received an intraperitoneal injection of BrdU (50 mg/Kg in 50 mM PBS) on different starting days after toxin injection (from day 1 to day 4, day 4 to 8, 8 to 12, and 12 to 15) ( Figure 1A ). All rats were sacrificed 15 days post-lesion by transcardial perfusion of 4% paraformaldehyde. Cell proliferation was assessed by BrdU immunohistochemistry and cells were stereologically counted using the optical fractionator method (see bellow). Once the time of the proliferation peak was determined ( Figure 2B ), all rats sacrificed on day 15 or 38 post-lesion received an intraperitoneal injection of BrdU (50 mg/Kg in 50 mM PBS) from day 4 to day 8 postlesion. The fate of the newly generated cells at the proliferation peak was examined in the group of animals sacrificed 30 days after the last BrdU injection (day 38 postlesion).
Real-time RT-PCR
At the indicated post-lesion time ( Figure 1B ), 6 rats from each group were anaesthetized and decapitated. The brain was then removed and the HF dissected, before being quickly frozen in liquid N 2 and stored at -80°C prior to use. Total RNA was isolated using the TRIzol reagent (Invitrogen, Paisley, UK), following manufacturer's instructions. We synthesized 2 µg of first-strand cDNA with random primers using the First Strand cDNA Synthesis kit. The RT reaction was performed at 42°C for 60 minutes followed by 5 minutes at 70°C. Real-time PCR was conducted using the SensiFAST TM SYBR No-ROX One-Step mix according to manufacturer's instructions.
The PCR program was: 2 minutes at 95°C for denaturation; 45 cycles of 15 seconds at 95°C for amplification and 1 minute at 60°C for final extension. For each target gene, the expression level was normalized to the mRNA level of GAPD. Primer sequences for target gene and endogenous controls are presented in Table 1 . The ΔΔCT method was used to analyze the data as described by Bookout et al. (2006) .
Histology, immunohistochemistry, and image analysis
After anesthesia, rats were transcardially perfused with 300 ml of 0.01 M PBS followed by 300 ml of 4% (w/v) paraformaldehyde in 0.01 M phosphate buffer (PB). The brains were removed, post-fixed, and transferred to 15% (w/v) sucrose in PB at 4ºC. The brains were then frozen with powdered dry ice and stored at -80ºC until use. Eight series of 25 adjacent 14-µm coronal sections from the whole hippocampus were obtained from the brains and mounted on poly-L-lysine-pretreated slides (10% w/v in distilled water).
Standard Nissl staining was performed to evaluate the areas of neuronal loss and the morphometry of the HF. Microglial cells were labeled for isolectin B4 Immunohistochemistry was carried out as previously described using the biotin-avidin-peroxidase method. Anti-GFAP antibodies were used to assess were obtained and analyzed. The co-localization study also included the determination of Pearson's "r" coefficient, the overlap coefficient R, and the overlap coefficients for the green (k1) and red (k2) channels. All image analyses were performed with FluoColoc (ExploraNova, France) and ImageJ software.
Statistical analysis
For each parameter, the normal distribution of data was tested analyzing Kurtosis and 
RESULTS

Diazoxide attenuates the NMDA-induced neurodegenerative process in the rat hippocampus
In our previous study we showed that activated microglia expressed K ATP channels in the rat NMDA-lesioned hippocampus. To monitor this microglial expression, here, we quantified by RT-qPCR the mRNA levels of Kir6.1, Kir6.2, SUR1 and SUR2 in the hippocampus of sham and NMDA-lesioned rats at different post-lesion times. We also analyzed the effects of Dzx on these expression levels ( Table 2 ). Compared to sham rats, we found significant increases in Kir6.1 (2.59-fold; p = 0.009) and SUR2 (2.21-fold; p = 0.007) expression 5 days after the NMDA injection. This increase in expression was not significant at longer times after lesion induction. Dzx significantly increased SUR2 expression only on day 38 post-lesion (2.47-fold; p = 0.046; Table 2 ).
We then studied the long-term effects of chronic Dzx oral administration on excitotoxicity-induced neurodegeneration. Inspections of Nissl-stained sections revealed that 20 nmol NMDA produced major disorganization, neuronal loss and gliosis in all the layers of the HF. A daily dose of 1 mg/kg/day Dxz attenuated these NMDA-induced effects on days 15 and 38 post-lesion ( Figure 3A -C). We measured morphological changes in the lesioned hippocampal area using Nissl-stained sections. We noted that 50 mM PBS microinjection caused no significant lesion in the hippocampus except for the needle puncture wound, at any of the four studied time points ( Figure 3G ). By contrast, 20 nmol NMDA induced a progressive increase in the lesioned area that reached a maximal size covering 41 ± 5% of the whole hippocampus 38 days after lesion induction (p = 0.0004). This area of the lesion was 24 ± 3% smaller (p = 0.015) in the hippocampus of NMDA-lesioned rats receiving a daily dose of Dzx ( Figure 3G ).
We then assessed the area of NMDA-induced neuronal loss in the pyramidal CA and granular DG layers of NeuN-immunostained HF ( Figure 3D-F) . In NMDA rats, the area of neuronal loss covered 28 ± 7% of the pyramidal CA1 and CA2 layers 5 days postlesion, progressively reaching a maximal value of 71 ± 9% on day 38 post-lesion (p = 0.0099). Dzx treatment decreased this area of neuronal loss by 31 ± 4% on day15 postlesion; however there was no significant effect on day 38 post-lesion ( figure 3H ). In the granular layer of the DG, Dzx reduced the area of NMDA-induced neuronal loss by 42 ± 8% on day 15 post-lesion (p = 0.0450), this decrease remaining significant on day 38
post-lesion ( Figure 3I ).
We studied microglial reaction by IB4 histochemistry ( Figure 4A -C). Whilst there was no significant microglial reaction in sham rats, except that associated with the needle puncture wound, NMDA induced microglial reactivity covering 36.50 ± 4.33% of the total hippocampal area on day 5 post-lesion (p = 0.0005). This area increased with time to reach a maximal value of 61 ± 7% of the whole HF on day 15 post-lesion ( Figure   4G ), slightly decreasing on day 38 post-lesion. Dzx treatment significantly reduced this microglial reaction area to the 33 ± 5% of the whole hippocampus on day 15 (reduction of 47 ± 6%; p = 0.0032), which remained decreased on day 38 post-lesion ( Figure 4G ).
The area of NMDA-induced astrogliosis was assessed by GFAP-immunohistochemistry ( Figure 4D-F) . In sham animals, this area was restricted to the needle puncture wound, reaching a maximal value of 6.5 ± 4% of the whole hippocampal area 5 days post-lesion ( Figure 4H ). We detected reactive astrocytes in 24.36 ± 5.69% of the hippocampal area 5 days after NMDA microinjection. This area of astrogliosis reached a maximal size of 49 ± 4% on day 15 post-lesion (p = 0.0005), slightly decreasing on day 38 post-lesion.
Dzx decreased the area of NMDA-induced astrogliosis by 26 ± 6% on day 15 postlesion (p = 0.0456), this decrease remaining significant 38 days after lesion induction ( Figure 4H ).
Diazoxide enhances NMDA-induced neurogenesis in the rat hippocampus
NMDA induced cell proliferation in the hippocampus that reached a maximal value 4 to 8 days after lesion induction, as detected by BrdU immunohistochemistry ( Figure 2B ).
To determine the cell type of the newly generated cells, we performed double immunohistochemical staining and confocal microscopy to identify cells stained with
BrdU and a cell-specific marker 38 days post-lesion. BrdU-NeuN doubleimmunostained cells in the lesioned area accounted for 40 ± 3% of all the mitogenic cells ( Figure 5A ). Of the cells co-expressiong BrdU and NeuN, 78 ± 5% were in the lesioned hippocampal parenchyma and CA layers, while only 22 ± 1% where in the DG ( Figure 5B ). Only 5.8 ± 0.7% of BrdU-positive cells displayed IB4 staining and were homogeneously distributed throughout the hippocampal lesioned area ( Figure 5C-D) .
Meanwhile, 51 ± 4% of BrdU-positive cells were immunoreactive for GFAP. These cells were widely distributed throughout the entire hippocampal lesioned area, with only 3.7 ± 0.2% located in the DG (Figure 5E-F) . Dzx treatment did not modify the number and distribution of BrdU-positive cells but did significantly affect cell fate ( Figure 5G) since only 8.5 ± 1% of BrdU-positive cells were also immunoreactive for GFAP whereas the 32 ± 3% were positive for IB4 and the remaining 59.5 ± 7%
immunopositive for NeuN ( Figure 5B , D, F, G).
We monitored the location of DCX-immunostained cells to study the neurogenic time decrease in the area of the lesioned hippocampus ( Figures 5B, 6H ).
Diazoxide enhances the NMDA-induced presence of SP8-GFAP-positive cells in the hippocampus
As most neuroblasts and newly generated neurons were not mainly located in the DG, we evaluated their putative SVZ origin by immunohistochemically analyzing the transcription factor Sp8. Cells immunopositive for Sp8 were detected in the SVZ along the entire lateral wall of the ventricles, but there was no specific staining in the intact SGZ of the DG ( Figure 7A , B) On day 15 post-lesion, Sp8 immunopositive cells were present in all the lesioned hippocampal subfields, mainly in the oriens and radiatum strata of CA1, the lacunosum moleculare, and the ventral part of the hippocampus near the thalamus ( Figure 7C ). These cells presented Sp8 staining in the nucleus and cytoplasm, some showing intense immunostaining in the cellular processes ( Figure 7D ). ischemia, trauma, and neurotoxicants (Robin et al., 2011; Shukry et al., 2015) . Recently, we and others have reported novel roles for Dzx as an anti-inflammatory agent, which could contribute to the neuroprotective effects. Dzx has been shown to prevent microglial TNF , NO and interleukin-6 production after activation with different stimuli in vitro (Zhou et al., 2008; Virgili et al., 2011) . Here, our in vivo results demonstrated that Dzx preserves neurons and decreases microglial reaction against an excitotoxic neurodegenerative insult, possibly through its anti-inflammatory action.
Different CNS cell types, including neurons (Humphries and Dart, 2015) , oligodendrocytes (Fogal et al., 2010) and microglia (Virgili et al., 2011; Ortega et al., 2012) , express K ATP channels as a combination of Kir6.2 and SUR1 subunits. K ATP channels are also expressed by endothelial cells, where they could be involved on the vascular response to physiological events (Rosenblum, 2003) . Thus, Dzx not only acts on microglial cells, but also on other cell types in a dose-dependent manner. At the dose used in the present study (1 mg/kg/day) we found no effects of Dzx on peripheral glucose concentration, confirming the specificity of Dzx activity on CNS cells.
In our model, oral administration of Dzx at a low concentration (1mg/kg/day) preserved NMDA-induced cell death. Other studies in different animal models have shown that Dzx protects against cell death from excitotoxicity or inflammation, generating beneficial outcomes (Zhou et al., 2008; Liu et al., 2010; Virgili et al., 2011) and modulating the innate immune response (Virgili et al., 2014) .
The mechanisms underlying such actions of Dzx are not yet completely understood.
Dzx-mediated neuroprotection is thought to be linked to the mitochondria, which are the main ATP-generating sites in the cell. Microglial activation involves a metabolic reprograming that leads to potentiation of anaerobic glycolysis (Gimeno-Bayón et al., 2014), higher numbers of mitochondria labeled with [ 3 H]PK11195 (Bernal et al., 2009) and increased mitoK ATP channel expression . Activation of mitoK ATP channels increases potassium flux into the mitochondrial matrix and avoids excessive mitochondrial contraction that is deleterious for electron transport (Cancherini et al., 2003) . Indeed, cells treated with Dzx demonstrate favorable energy profiles with limited damage following stress challenges (Iwai et al., 2000) . Furthermore, Dzx has been reported to provide cardioprotection through mitoK ATP activation (Henn et al., 2015) . Thus, Dzx could exert its neuroprotective effects through increasing the ATP/ADP ratio in the mitochondria and cytoplasm of reactive microglia. If we consider the specific action of Dzx on plasmalemma K ATP channels, K ATP channel activity at the cell membrane would therefore be regulated by ATP-mediated inhibition and Dzxinduced activation .
Our in vivo results revealed that NMDA-induced excitotoxicity increased the proliferation and maturation of newborn neurons in the lesioned HF. Many studies have described enhanced adult SGZ neurogenesis after acute injury such as ischemia, traumatic brain injury, experimentally induced epilepsy and trimethyltin intoxication (Corvino et al., 2005; Kleindienst et al., 2005; Hattiangady and Shetty, 2008) . However, the induction of proliferation in those studies is not sustained long term and the number of newly generated neurons is limited. The reasons for this limited neurogenesis could be asymmetric or symmetric division of newborn cells leading to mature glial cells and the formation of the glial scar (Sofroniew, 2009; Sierra et al., 2015) or newly generated neurons hardly integrating into the hippocampal circuits and thus, degenerating (Sun et al., 2005) . In any case, this neurogenesis eventually accelerates the depletion of the neural stem cell pool (Sierra et al., 2015; Zhang et al., 2015) . However, here, we report a new finding of neuroblasts and newly generated neurons being detected in the lesioned HF by both DCX-immunohistochemistry and BrdU-NeuN double staining.
Moreover, the expression of the transcription factor Sp8 by GFAP-positive cells in the injured hippocampus indicates that an excitotoxic lesion induces neurogenesis by eliciting the migration of progenitors from the SVZ and/or reprograming reactive astrocytes in the lesioned HF.
Sp8-positive cells are the major population of olfactory bulb GABAergic interneurons constantly produced in the SVZ (Waclaw et al., 2006; Liu et al., 2009) and are not present in the SGZ of the DG. The presence of several Sp8-positive cells in the lesioned HF may reflect infiltration of blood-borne cells (Zhang et al., 2004) . However, the Sp8-GFAP positive cells we found indicate either a robust recruitment of neuroblasts from the SVZ into the damaged hippocampus or reactive astrocytes acquiring progenitor cell properties after injury, as previously described for ischemic brain injury (Sirko et al., 2013) . In either case the appearance of Sp8-positive neuroblasts in the lesioned hippocampus would compensate for the reduced neuroblast pool in the SGZ. It is important to point out that most DCX-positive cells were not immunopositive for BrdU, suggesting that migration or the appearance of these new neuroblasts in the damaged hippocampus is not preceded by the induction of cell proliferation. The constitutive expression of Sp8 by neuroblasts during the course of the study, which has been also observed in the striatum after stroke (Liu et al., 2009) , indicates that the intrinsic differentiation program of adult neuroblasts is not altered by brain area-specific external factors or cerebral injury.
Our data indicate that neurogenesis is a microglial-dependent process, with microglia being required for controlling of progenitor cell migration and differentiation (Sato, 2015) and exacerbated microgliosis being detrimental for neurogenesis (Solano Fonseca et al., 2016) . In the pathogenic brain, together with reactive astrocytes, microglia produce trophic factors that promote neurogenesis (Ribeiro Xavier et al., 2015) and inflammatory compounds that inhibit neurogenesis (Monje et al., 2003; Song and Wang, 2011; Ji et al., 2013; Mattei et al., 2014) . Given that Dzx decreased chronic microglial reaction and the extent of the lesion in our model, and that in vitro Dzx attenuates the pro-inflammatory activity of reactive microglia (Zhou et al., 2008; Virgili et al., 2011) , Dzx may promote neurogenesis by reducing the synthesis of inflammatory compounds. As there is no evidence of K ATP channel expression in neuroblasts (Ortega et al., 2014) , the effect of Dzx on neurogenesis could be through controlling microglial reactivity. Thus, by regulating the reactive phenotype of microglia through K ATP channel activation, we Dzx increased the number of newly generated NeuN-positive cells and the occurrence of Sp8-GFAP-positive cells in the lesioned HF in the present study. The latter cells could have migrated from the pool located in the SVZ or from layers I and II of the cerebral cortex (Zhang et al., 2015) . Whatever the case, the mechanisms underlying microglial recruitment of these cells remain to be elucidated.
Not all anti-inflammatory therapies may be beneficial for restoring neurogenesis. In a previous study, we demonstrated that blocking of microglial K ATP -channels enhanced microglial release of MCP-1 and neurosphere proliferation, while partly affecting cell fate determination (Ortega et al., 2014) . These results were consistent with those of other showing that neuroinflammation promotes neurogenesis. For example, antiinflammatory treatment with minocycline does not affect neurogenesis (Ng et al., 2012) , nor reduce proliferation of SVZ progenitors after inflammation (Deierborg et al., 2010) .
Furthermore, some inhibitors of cyclooxigenase-2, which is highly expressed by reactive microglia, are potent suppressors of neurogenesis (Goncalves et al., 2010) .
These findings reinforce the idea that some pro-inflammatory modulators do not inhibit adult neurogenesis. Thus, as microglial activation mediates inflammation at the site of injury (Domercq et al., 2013) and neuroblasts from the SVZ respond positively to inflammatory mediators (Ekdahl et al., 2009) , therapies completely abrogating inflammation could be detrimental under certain conditions in regulating neurogenesis after injury. Thus, compounds like Dzx that modulate, but do not abolish, microglial inflammatory activity could be used to promote neurogenesis in cerebral damage.
Newborn hippocampal neurons after ischemia have been reported to be partially functional three months after the injury and to ameliorate the induced neurological deficits in rats (Nakatomi et al., 2002) . However, the fact that neuroblasts retain their SVZ phenotype during the course of the study may indicate an aberrant neurogenesis and impairment of hippocampal functioning, as described in pathological situations such as stress, depression and epilepsy (Ming and Song, 2011) . It would be interesting to ascertain the role of the newly generated Sp8-positive cells in the injured HF, as they may act as newborn type II astrocytes or differentiate into neurons with the same function as those of hippocampal GABAergic interneurons (Zhang et al., 2015) . If the latter is correct, this would reinforce the use of therapeutic approaches promoting the long-term capacity of the brain to regenerate hippocampal function in neurological disorders (Picard-Riera et al., 2004) . However, the main degenerating cells in the injured hippocampus are glutamatergic pyramidal neurons, whose regeneration should be considered when developing therapies. 
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